OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Remdesivir against COVID-19 and Other Viral Diseases
Jakob J Malin, Isabelle Suárez, Vanessa Priesner, et al.
Clinical Microbiology Reviews (2020) Vol. 34, Iss. 1
Open Access | Times Cited: 260
Jakob J Malin, Isabelle Suárez, Vanessa Priesner, et al.
Clinical Microbiology Reviews (2020) Vol. 34, Iss. 1
Open Access | Times Cited: 260
Showing 1-25 of 260 citing articles:
Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 382
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 382
Remdesivir for the treatment of COVID-19
Kelly Ansems, Felicitas Grundeis, Karolina Dahms, et al.
Cochrane library (2021) Vol. 2021, Iss. 8
Open Access | Times Cited: 194
Kelly Ansems, Felicitas Grundeis, Karolina Dahms, et al.
Cochrane library (2021) Vol. 2021, Iss. 8
Open Access | Times Cited: 194
Broad-Spectrum Antiviral Strategies and Nucleoside Analogues
Robert J. Geraghty, Matthew T. Aliota, Laurent Bonnac
Viruses (2021) Vol. 13, Iss. 4, pp. 667-667
Open Access | Times Cited: 140
Robert J. Geraghty, Matthew T. Aliota, Laurent Bonnac
Viruses (2021) Vol. 13, Iss. 4, pp. 667-667
Open Access | Times Cited: 140
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 136
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 136
Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
Oral antiviral treatments for COVID-19: opportunities and challenges
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1255-1278
Open Access | Times Cited: 70
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1255-1278
Open Access | Times Cited: 70
Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
Vanessa Monteil, Matheus Dyczynski, Volker M. Lauschke, et al.
EMBO Molecular Medicine (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 103
Vanessa Monteil, Matheus Dyczynski, Volker M. Lauschke, et al.
EMBO Molecular Medicine (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 103
Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19
Mercedes Prudencio, Young Erben, Christopher P. Marquez, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 602
Open Access | Times Cited: 76
Mercedes Prudencio, Young Erben, Christopher P. Marquez, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 602
Open Access | Times Cited: 76
A deep learning method for repurposing antiviral drugs against new viruses via multi-view nonnegative matrix factorization and its application to SARS-CoV-2
Xiaorui Su, Lun Hu, Zhu‐Hong You, et al.
Briefings in Bioinformatics (2021) Vol. 23, Iss. 1
Closed Access | Times Cited: 69
Xiaorui Su, Lun Hu, Zhu‐Hong You, et al.
Briefings in Bioinformatics (2021) Vol. 23, Iss. 1
Closed Access | Times Cited: 69
Recent review of COVID-19 management: diagnosis, treatment and vaccination
Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1120-1148
Open Access | Times Cited: 55
Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1120-1148
Open Access | Times Cited: 55
Digital PCR Applications in the SARS-CoV-2/COVID-19 Era: a Roadmap for Future Outbreaks
Raphael Nyaruaba, Caroline Mwaliko, David Dobnik, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 48
Raphael Nyaruaba, Caroline Mwaliko, David Dobnik, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 48
Experimental Models of COVID-19
Luis A. Caldera-Crespo, Michael J. Paidas, Sabita Roy, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 11
Open Access | Times Cited: 40
Luis A. Caldera-Crespo, Michael J. Paidas, Sabita Roy, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 11
Open Access | Times Cited: 40
Efficacy of repurposed antiviral drugs: Lessons from COVID-19
Miguel Ángel Martı́nez
Drug Discovery Today (2022) Vol. 27, Iss. 7, pp. 1954-1960
Open Access | Times Cited: 40
Miguel Ángel Martı́nez
Drug Discovery Today (2022) Vol. 27, Iss. 7, pp. 1954-1960
Open Access | Times Cited: 40
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
Nada A. Ashour, Ayman Abo Elmaaty, Amany A. Sarhan, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 685-715
Open Access | Times Cited: 40
Nada A. Ashour, Ayman Abo Elmaaty, Amany A. Sarhan, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 685-715
Open Access | Times Cited: 40
Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
Ashley Jia Wen Yip, Zheng Yao Low, Vincent Chow, et al.
Viruses (2022) Vol. 14, Iss. 6, pp. 1345-1345
Open Access | Times Cited: 38
Ashley Jia Wen Yip, Zheng Yao Low, Vincent Chow, et al.
Viruses (2022) Vol. 14, Iss. 6, pp. 1345-1345
Open Access | Times Cited: 38
Insights into the Adsorption Properties of Mixed Matrix Membranes (Pebax 1657-g-Chitosan-PVDF-Bovine Serum Albumin@ZIF-CO3-1) for the Antiviral COVID-19 Treatment Drugs Remdesivir and Nirmatrelvir: An In Silico Study
Iman Salahshoori, Narjes Montazeri, Amirhosein Yazdanbakhsh, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 26, pp. 31185-31205
Closed Access | Times Cited: 33
Iman Salahshoori, Narjes Montazeri, Amirhosein Yazdanbakhsh, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 26, pp. 31185-31205
Closed Access | Times Cited: 33
Remdesivir: A Review in COVID-19
Hannah A. Blair
Drugs (2023) Vol. 83, Iss. 13, pp. 1215-1237
Open Access | Times Cited: 28
Hannah A. Blair
Drugs (2023) Vol. 83, Iss. 13, pp. 1215-1237
Open Access | Times Cited: 28
Emergence of Marburg virus: a global perspective on fatal outbreaks and clinical challenges
Shriyansh Srivastava, Deepika Sharma, Sachin Kumar, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 27
Shriyansh Srivastava, Deepika Sharma, Sachin Kumar, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 27
COVID-19 and atrial fibrillation: Intercepting lines
Maria Donniacuo, Antonella De Angelis, Concetta Rafaniello, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 24
Maria Donniacuo, Antonella De Angelis, Concetta Rafaniello, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 24
Antimicrobial peptides as therapeutics: Confronting delivery challenges to optimize efficacy
Fahim Asif, Sabbir Uz Zaman, Md. Kamrul Hasan Arnab, et al.
The Microbe (2024) Vol. 2, pp. 100051-100051
Open Access | Times Cited: 13
Fahim Asif, Sabbir Uz Zaman, Md. Kamrul Hasan Arnab, et al.
The Microbe (2024) Vol. 2, pp. 100051-100051
Open Access | Times Cited: 13
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Small Molecule Drugs Targeting Viral Polymerases
Deborah Palazzotti, Martina Sguilla, Giuseppe Manfroni, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 661-661
Open Access | Times Cited: 7
Deborah Palazzotti, Martina Sguilla, Giuseppe Manfroni, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 661-661
Open Access | Times Cited: 7
Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies
Wissam H. Faour, Ali Choaib, Elio Issa, et al.
Inflammation Research (2021) Vol. 71, Iss. 1, pp. 39-56
Open Access | Times Cited: 49
Wissam H. Faour, Ali Choaib, Elio Issa, et al.
Inflammation Research (2021) Vol. 71, Iss. 1, pp. 39-56
Open Access | Times Cited: 49
Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
Norma A. Valdez‐Cruz, Enrique García‐Hernández, Clara Espitia, et al.
Microbial Cell Factories (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 48
Norma A. Valdez‐Cruz, Enrique García‐Hernández, Clara Espitia, et al.
Microbial Cell Factories (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 48
Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis
Rachel Beckerman, Andrea Gori, Sushanth Jeyakumar, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 30
Rachel Beckerman, Andrea Gori, Sushanth Jeyakumar, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 30
